REFINITIV

DELTA REPORT

10-Q

NXTC - NEXTCURE, INC.

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	597
CHANGES	109
DELETIONS	230
ADDITIONS	258

REFINITIV

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2023 March 31, 2024

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to .

Commission File Number: 001-38905

NextCure, Inc.

(Exact name of registrant as specified in its charter)

Delaware	**47-5231247**
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
9000 Virginia Manor Road, Suite 200 **Beltsville, Maryland**	**20705**
(Address of principal executive offices)	(Zip Code)

(240) 399-4900

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered:
Common Stock, $0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 30, 2023 April 30, 2024, the registrant had 27,903,027 27,973,289 shares of common stock, par value $0.001 per share, issued and outstanding.

Table of Contents

NextCure, Inc.

Form 10-Q

For the Quarter Ended September 30, 2023 March 31, 2024

TABLE OF CONTENTS

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

NEXTCURE, INC.
CONDENSED BALANCE SHEETS
(unaudited, in thousands, except share and per share amounts)

	September 30, 2023	December 31, 2022	March 31, 2024	December 31, 2023
Assets				
Current assets:				
Cash and cash equivalents	$ 19,519	$ 26,630	$ 18,358	$ 13,082
Marketable securities	98,687	133,281	77,643	95,217
Prepaid expenses and other current assets	4,478	4,072	6,551	4,426
Total current assets	122,684	163,983	102,552	112,725
Property and equipment, net	9,844	11,897	7,097	9,033
Right of use assets	4,557	5,016	3,632	4,398
Other assets	2,854	3,265	1,878	1,882
Total assets	$ 139,939	$ 184,161	$ 115,159	$ 128,038
Liabilities and Stockholders' Equity				
Current liabilities:				
Accounts payable	$ 2,602	$ 4,270	$ 4,491	$ 2,330
Accrued liabilities and other liabilities	3,950	4,857	5,092	4,553
Total current liabilities	6,552	9,127	9,583	6,883
Lease liabilities, long term	6,120	6,605	5,773	5,949
Other long-term liabilities	815	899	755	785
Total liabilities	13,487	16,631	16,111	13,617

Stockholders' equity:				
Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; No shares issued and outstanding at September 30, 2023 and December 31, 2022	—	—		
Common stock, par value of $0.001 per share; 100,000,000 shares authorized at September 30, 2023 and December 31, 2022; 27,839,968 and 27,774,536 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	28	28		
Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; No shares issued and outstanding at March 31, 2024 and December 31, 2023			—	—
Common stock, par value of $0.001 per share; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 27,903,627 and 27,903,027 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively			28	28
Additional paid-in capital	437,042	430,755	440,791	439,097
Accumulated other comprehensive loss	(603)	(1,494)	(182)	(222)
Accumulated deficit	(310,015)	(261,759)	(341,589)	(324,482)
Total stockholders' equity	126,452	167,530	99,048	114,421
Total liabilities and stockholders' equity	$ 139,939	$ 184,161	$ 115,159	$ 128,038

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

NEXTCURE, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,		Three Months Ended March 31,	
	2023	2022	2023	2022	2024	2023
Operating expenses:						
Research and development	$ 11,010	$ 13,528	$ 36,104	$ 41,377	$ 11,398	$ 11,647
General and administrative	4,608	5,711	15,743	16,761	4,364	5,424
Restructuring and asset impairment charges					2,542	—
Total operating expenses	15,618	19,239	51,847	58,138	18,304	17,071
Loss from operations	(15,618)	(19,239)	(51,847)	(58,138)	(18,304)	(17,071)
Other income, net	1,317	328	3,591	705	1,197	975

Net loss	$ (14,301)	$ (18,911)	$ (48,256)	$ (57,433)	$ (17,107)	$ (16,096)
Net loss per common share - basic and diluted	$ (0.51)	$ (0.68)	$ (1.73)	$ (2.07)	$ (0.61)	$ (0.58)
Weighted-average shares outstanding - basic and diluted	27,839,968	27,748,844	27,814,655	27,734,271	27,903,040	27,774,536
Comprehensive loss:			.			
Net loss	$ (14,301)	$ (18,911)	$ (48,256)	$ (57,433)	$ (17,107)	$ (16,096)
Unrealized gain (loss) on marketable securities	322	(56)	891	(1,733)		
Unrealized gain on marketable securities					40	691
Total comprehensive loss	$ (13,979)	$ (18,967)	$ (47,365)	$ (59,166)	$ (17,067)	$ (15,405)

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

NEXTCURE, INC.
CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY
(unaudited, in thousands, except share data) data)

	Three Months Ended March 31, 2024					
	Stockholders' Equity					
			Additional	Accumulated Other		
	Common Stock		Paid-in	Comprehensive	Accumulated	Stockho
	Shares	Amount	Capital	Loss	Deficit	Equ
Balance as of December 31, 2023	27,903,027	$ 28	$ 439,097	$ (222)	$ (324,482)	$ 11
Stock-based compensation	—	—	1,693	—	—	
Exercise of stock options	600	—	1	—	—	
Unrealized loss on marketable securities, net of tax	—	—	—	40	—	
Net loss	—	—	—	—	(17,107)	(1
Balance as of March 31, 2024	27,903,627	$ 28	$ 440,791	$ (182)	$ (341,589)	$ 9

Nine Months Ended September 30, 2023	Three Months Ended March 31, 2023
Stockholders' Equity	Stockholders' Equity

	Common Stock		Additional Paid-in	Accumulated Other Comprehensive	Accumulated	Stockholders'
	Shares	Amount	Capital	Loss	Deficit	Equity
Balance as of December 31, 2022	27,774,536	$ 28	$ 430,755	$ (1,494)	$ (261,759)	$ 167,530
Stock-based compensation	—	—	2,078	—	—	2,078
Unrealized gain on marketable securities, net of tax $0	—	—	—	691	—	691
Net loss	—	—	—	—	(16,096)	(16,096)
Balance as of March 31, 2023	27,774,536	$ 28	$ 432,833	$ (803)	$ (277,855)	$ 154,203
Stock-based compensation	—	—	2,125	—	—	2,125
Exercise of stock options	5,057	—	5	—	—	5
Issuance of shares under ESPP	60,375	—	78	—	—	78
Unrealized loss on marketable securities, net of tax $0	—	—	—	(122)	—	(122)
Net loss	—	—	—	—	(17,859)	(17,859)
Balance as of June 30, 2023	27,839,968	$ 28	$ 435,041	$ (925)	$ (295,714)	$ 138,430
Stock-based compensation	—	—	2,001	—	—	2,001
Unrealized gain on marketable securities, net of tax $0	—	—	—	322	—	322
Net loss	—	—	—	—	(14,301)	(14,301)
Balance as of September 30, 2023	27,839,968	$ 28	$ 437,042	$ (603)	$ (310,015)	$ 126,452

Nine Months Ended September 30, 2022

	Stockholders' Equity					
	Common Stock		Additional Paid-in	Accumulated Other Comprehensive	Accumulated	Stockholders'
	Shares	Amount	Capital	Loss	Deficit	Equity
Balance as of December 31, 2021	27,680,997	$ 28	$ 421,047	$ (663)	$ (187,026)	$ 233,386
Stock-based compensation	—	—	2,628	—	—	2,628
Exercise of stock options	44,165	—	60	—	—	60
Unrealized loss on marketable securities, net of tax $0	—	—	—	(1,536)	—	(1,536)
Net loss	—	—	—	—	(20,602)	(20,602)
Balance as of March 31, 2022	27,725,162	$ 28	$ 423,735	$ (2,199)	$ (207,628)	$ 213,936
Stock-based compensation	—	—	2,242	—	—	2,242
Exercise of stock options	6,255	—	6	—	—	6
Issuance of shares under ESPP	17,427	—	73	—	—	73
Unrealized loss on marketable securities, net of tax $0	—	—	—	(141)	—	(141)
Net loss	—	—	—	—	(17,920)	(17,920)
Balance as of June 30, 2022	27,748,844	$ 28	$ 426,056	$ (2,340)	$ (225,548)	$ 198,196
Stock-based compensation	—	—	2,312	—	—	2,312
Unrealized loss on marketable securities, net of tax $0	—	—	—	(56)	—	(56)
Net loss	—	—	—	—	(18,911)	(18,911)
Balance as of September 30, 2022	27,748,844	$ 28	$ 428,368	$ (2,396)	$ (244,459)	$ 181,541

The accompanying notes are an integral part of these unaudited condensed financial statements.

NEXTCURE, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)

	Nine Months Ended September 30,		Three Months Ended March 31,	
	2023	2022	2024	2023
Cash flows from operating activities:				
Net loss	$ (48,256)	$ (57,433)	$(17,107)	$(16,096)
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation and amortization	2,860	3,117	790	960
Amortization of premiums and discounts on marketable securities	(432)	2,594	(304)	82
Stock-based compensation	6,204	7,182	1,693	2,078
Asset impairment			1,787	—
Noncash operating lease expense	426	—	150	150
Changes in operating assets and liabilities:				
Prepaid expenses and other assets	38	234	(2,109)	1,089
Accounts payable	(1,668)	(95)	2,161	(2,351)
Accrued liabilities and other liabilities	(907)	(536)	539	(551)
Lease liabilities	(485)	—	(176)	(113)
Other long-term liabilities	(84)	—	(30)	(27)
Net cash used in operating activities	(42,304)	(44,937)	(12,606)	(14,779)
Cash flows from investing activities:				
Sales and maturities of marketable securities	97,605	78,029	29,055	49,773
Purchases of marketable securities	(61,688)	(13,267)	(11,137)	(31,403)
Purchases of property and equipment	(807)	(1,251)	(37)	(248)
Net cash provided by investing activities	35,110	63,511	17,881	18,122
Cash flows from financing activities:				
Proceeds from exercise of stock options	5	66	1	—
Proceeds from shares issued under ESPP	78	73		
Net cash provided by financing activities	83	139	1	—
Net increase (decrease) in cash and cash equivalents	(7,111)	18,713		
Net increase in cash and cash equivalents			5,276	3,343
Cash and cash equivalents – beginning of period	26,630	12,376	13,082	26,630
Cash and cash equivalents – end of period	$ 19,519	$ 31,089	$ 18,358	$ 29,973
Supplemental disclosures of cash flow information:				
Cash paid for interest	$ 62	$ 68	$ 19	$ 21

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited) (*unaudited*)

1. Nature of the Business

Organization

NextCure, Inc. (“NextCure” or the “Company”) was incorporated in Delaware in September 2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery proteins. We focus on advancing therapies that leverage our core strengths in Immuno-Oncology (“FIND-IO”) platform, understanding biological pathways and biomarkers, the Company studies various immune interactions of cells, including in order to discover the tumor microenvironment, and understand targets and structural components of immune cells and their functional impact the role each interaction plays in order to develop immunomedicines. a biologic response. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company’s product candidates, building and optimizing the Company’s manufacturing capabilities and conducting discovery, research and development activities for the Company’s product candidates, discovery programs identifying business development opportunities, raising capital and its FIND-IO platform. securing intellectual property rights related to the Company’s product candidates.

Liquidity

The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through September 30, 2023 March 31, 2024, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company’s former agreement with Eli Lilly and Company, which was terminated in March 2020. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.

As of September 30, 2023 March 31, 2024, the Company had cash, cash equivalents and marketable securities of $118.2 million $96.0 million. The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its planned operations for at least the next twelve months from the issuance of these financial statements.

2. Summary of Significant Accounting Policies

The following significant accounting policy is policies are in addition to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023 (the “Annual Report”).

Collaboration Arrangements ***Restructuring Charges***

The Company assesses whether collaboration agreements are subject recognizes restructuring charges related to Accounting Standards Codification (“ASC”) 808, Collaborative Arrangements ("ASC 808"), based on whether they involve joint

operating reorganization plans that have been implemented by management. In connection with these activities, involving two or more parties that are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activities.

A collaborative arrangement within the scope of ASC 808 may be partially (or entirely) within the scope of other guidance (including ASC 606). The Company evaluates the individual units of account (e.g., components) within a collaborative arrangement to assess the appropriate recognition and measurement. The Company accounts for components of a collaborative arrangement that are within the scope of other ASC guidance following the relevant provisions of that guidance rather than the guidance provided in ASC 808.

ASC 808 states that a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer for a distinct good or service (i.e., a unit of account). That is, the Company is required to apply the unit-of-account guidance in ASC 606 to determine the distinct components of a collaborative arrangement. If the counterparty is a customer for that distinct good or service (or bundle of goods and/or services), it is accounted for under ASC 606. For records restructuring charges at fair value for:

- contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vested or accumulate when the payment of benefits becomes probable and the amount can be reasonably estimated;
- one-time employee termination benefits to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn;
- contract termination costs when the Company cancels a contract in accordance with its terms; and
- costs to be incurred over the remaining contract term without economic benefit to the Company at the cease-use date.

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited) (*unaudited*)

units of account that are in For one-time employee terminations benefits, the scope of ASC 606, all of the guidance in ASC 606 applies, including the guidance on recognition, measurement, presentation and disclosure.

The Company accounts for collaborative arrangements or components of collaborative arrangements that are outside the scope of other guidance by analogy to the authoritative accounting literature or, if there is no appropriate analogy, by using a reasonable, rational and consistently applied accounting policy election. When evaluating an appropriate analogy to other accounting guidance or an accounting policy for a collaborative arrangement, the Company assesses the nature of the arrangement, the nature of its business operations and the contractual terms of the arrangement. The Company recognizes the shared costs incurred that liability in full on the communication date when future services are not within required or amortizes the scope liability ratably over the service period, if required. The fair value of other accounting literature as termination benefits reflects the Company's estimate of expected utilization of certain Company-funded post-employment benefits.

Long-Lived Asset Impairment Assessments

Long-lived assets, including operating lease assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a component comparison of the related expense in carrying amount of the period incurred asset group to

future net cash flows estimated by analogy the Company to ASC 730, Research and Development, and records reimbursements from counterparties as an offset be generated by such assets. If such asset group is considered to be impaired, the related research and development costs. impairment to be recognized is the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.

Basis of Presentation

The unaudited condensed financial statements include the accounts of the Company and have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the Company's audited financial statements and the notes thereto in the Annual Report.

Unaudited Financial Information

In the opinion of management, the information furnished reflects certain adjustments, all which are of a normal and recurring nature and are necessary for a fair presentation of the Company's financial position as of the reported balance sheet date and of the Company's results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.

Recently Issued Accounting Pronouncements

The Company qualifies as an emerging growth company ("EGC") as defined under the Jumpstart Our Business Startups Act (the "JOBS Act"). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies.

The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued by the Financial Accounting Standards Board ("FASB"). All other ASUs issued subsequent to the filing of the Company's Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company's financial position or results of operations.

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited) (*unaudited*)

3. Marketable Securities

Marketable securities consist of the following:

(in thousands)	September 30, 2023 Amortized Cost	Gross Unrealized Gain	Gross Unrealized Loss	Estimated Fair Value	March 31, 2024 Amortized Cost	Gross Unrealized Gain	Gross Unrealized Loss	Estimated Fair Value
Corporate bonds	$ 72,232	$ —	$ (473)	$ 71,759	$62,716	$ —	$ (151)	$62,565
U.S. Treasury and Government agencies	27,058	—	(130)	26,928	15,109	—	(31)	15,078
Total	$ 99,290	$ —	$ (603)	$ 98,687	$77,825	$ —	$ (182)	$77,643

(in thousands)	December 31, 2022 Amortized Cost	Gross Unrealized Gain	Gross Unrealized Loss	Estimated Fair Value	December 31, 2023 Amortized Cost	Gross Unrealized Gain	Gross Unrealized Loss	Estimated Fair Value
Corporate bonds	$ 133,163	$ —	$ (1,457)	$ 131,706	$73,334	$ 36	$ (210)	$73,160
U.S. Treasury and Government agencies	1,612	—	(37)	1,575	22,105	5	(53)	22,057
Total	$ 134,775	$ —	$ (1,494)	$ 133,281	$95,439	$ 41	$ (263)	$95,217

The Company uses the specific identification method when calculating realized gains and losses. For the three months ended September 30, 2023 March 31, 2024 and 2022, 2023, respectively, the Company recorded $0 and $7,000 $0 in realized gains or losses on available-for-sale securities, which is included in other income, net on the condensed statements of operations. For the nine months ended September 30, 2023 and 2022, respectively, the Company recorded $0 and $9,000 in realized gains on available-for-sale securities, which is included in other income, net on the condensed statements of operations. securities.

The Company reviewed all investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. As of September 30, 2023 March 31, 2024, the Company had investments with a total fair market value of $98.7 million $77.6 million in an unrealized loss position, of which $18.4 million $7.0 million were in a continuous unrealized loss position for more than twelve months. The Company analyzed the unrealized losses and determined that the prevailing high interest rates were the primary factor driving these changes, and such unrealized losses are temporary as the Company anticipates a full recovery of the amortized cost basis of these securities at maturity. After analyzing the securities in an unrealized loss position, the portion of these losses that relates to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.

The following table summarizes maturities of the Company's investments available-for-sale as of September 30, 2023 March 31, 2024:

(in thousands)	September 30, 2023 Cost	Fair Value	March 31, 2024 Cost	Fair Value
Maturities:				
Within 1 year	$ 97,274	$ 96,695	$74,885	$74,703
Between 1 to 2 years	2,016	1,992	2,940	2,940

Total investments available-for-sale	$ 99,290	$ 98,687	$77,825	$77,643

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)

The Company has classified all of its available-for-sale investments, including those with maturities beyond one year, as current assets on the accompanying condensed balance sheets based on the highly liquid nature of these investment securities and because these investment securities are considered available for use in current operations.

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(*unaudited*)

The Company has elected to report interest receivable from its marketable securities with prepaid expenses and other current assets on its balance sheet. Interest receivable included in prepaid expenses and other current assets totaled $0.6 million and $0.8 million as of March 31, 2024 and December 31, 2023, respectively.

4. Fair Value Measurements

The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.

Level 1—Quoted market prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3—Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.

To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The following tables set forth the fair value of the Company's financial assets by level within the fair value hierarchy as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023:

(in thousands)	September 30, 2023 Total	Quoted Prices in Active Markets or Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable (Level 3)	March 31, 2024 Total	Quoted Prices in Active Markets or Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable (Level 3)
Cash equivalents:								
Money market funds	$ 19,332	$ 19,332	$ —	$ —	$17,858	$ 17,858	$ —	$ —
Marketable securities:								
Corporate bonds	71,759	—	71,759	—	62,565	—	62,565	—
U.S. Treasury and Government agencies	26,928	—	26,928	—	15,078	—	15,078	—
Total	$ 118,019	$ 19,332	$ 98,687	$ —	$95,501	$ 17,858	$ 77,643	$ —

(in thousands)	December 31, 2022 Total	Quoted Prices in Active Markets or Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable (Level 3)	December 31, 2023 Total	Quoted Prices in Active Markets or Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable (Level 3)
Cash equivalents:								
Money market funds	$ 6,782	$ 6,782	$ —	$ —	$ 12,582	$ 12,582	$ —	$ —
Marketable securities:								
Corporate bonds	131,706	—	131,706	—	73,160	—	73,160	—
U.S. Treasury and Government agencies	1,575	—	1,575	—	22,057	—	22,057	—
Total	$ 140,063	$ 6,782	$ 133,281	$ —	$107,799	$ 12,582	$ 95,217	$ —

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited) ***(unaudited)***

The Company did not transfer any assets measured at fair value on a recurring basis between levels during the nine three months ended September 30, 2023 March 31, 2024.

5. Leases

The Company's lease portfolio consists of office space and laboratory facilities. All of the Company's leases are classified as operating leases. The terms of the Company's lease agreements currently extend through March 2030 and provide the Company with an option for a five-year extension. Under the terms of the leases, the Company pays base annual rent subject to fixed dollar increases each year and other normal operating expenses such as taxes, repairs, and maintenance. The Company evaluates renewal options at lease inception and on an ongoing basis and considers renewal options that the Company is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities in accordance with ASC Accounting Standards Codification ("ASC") 842. The leases do not require variable lease payments or residual value guarantees and do not contain restrictive covenants.

The leases do not provide an implicit rate; therefore, the Company uses its incremental borrowing rate as the discount rate when measuring the operating lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease.

Operating lease expense was $272,000 and $816,000 for both the three and nine months ended September 30, 2023, respectively. March 31, 2024 and March 31, 2023. Operating cash flows used for operating leases during the three and nine months ended September 30, 2023 March 31, 2024 and March 31, 2023 were $245,000 277,000 and $757,000 $246,000, respectively. As of September 30, 2023 March 31, 2024, the weighted-average remaining lease term was 6.50 6.0 years, and the weighted average discount rate was 7.46%.

Rent expense under operating leases was $248,000 and $739,000 for the three and nine months ended September 30, 2022, respectively.

As of September 30, 2023 March 31, 2024, the maturities of the Company's operating lease liabilities were as follows (in thousands), which are included in Accrued liabilities and other liabilities and Lease liabilities, long term in the accompanying balance sheet:

2023	$ 276			
2024	1,127	2024	$ 850	
2025	1,214	2025	1,214	
2026	1,355	2026	1,355	
2027	1,396	2027	1,396	
Thereafter	3,295	2028	1,438	
Total future minimum payments	8,663	Thereafter	1,857	
		Total future minimum		
Less: present value discount	(1,907)	payments	$ 8,110	
		Less: present value		
Present value of lease liabilities	$ 6,756	discount	(1,659)	
		Present value of lease		
		liabilities	$ 6,451	

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)

6. Stock-Based Compensation

Employee Equity Plans

The NextCure, Inc. 2015 Omnibus Incentive Plan (the "2015 Plan") was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants, and directors of the Company.

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(*unaudited*)

The NextCure, Inc. 2019 Omnibus Incentive Plan (the "2019 Plan") became effective on May 8, 2019, the date on which the Company's Registration Statement on Form S-1 filed in connection with the IPO was declared effective (the "Effective Date"). The Company's board of directors (the "Board") determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and cash bonus awards to the Company's officers, employees, non-employee directors and other key persons (including consultants).

The number of shares of common stock reserved for issuance under the 2019 Plan is 2,900,000 plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan automatically increase each January 1st during the term of the 2019 Plan by 4% of the number of shares of the Company's common stock outstanding on December 31st of the preceding calendar year or such lesser number of shares determined by the Board.

As of September 30, 2023 March 31, 2024, 2,108,622 931,387 shares were reserved for future grant under the 2019 Plan.

Stock options granted under the 2015 Plan and 2019 Plan (together, the "Plans") to employees generally vest over four years and expire after ten years.

A summary of stock option activity for awards under the Plans is presented below:

	Options Outstanding and Exercisable				Options Outstanding and Exercisable			
	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value(1) (in thousands)	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value(1) (in thousands)
Outstanding as of December 31, 2022	5,262,179	$ 11.44	7.6	$ 115				
Outstanding as of December 31, 2023					6,817,102	$ 8.83	7.3	$ 52
Granted	2,059,250	$ 1.55	—	—	2,835,600	$ 1.66	—	—
Exercised	(5,057)	$ 0.99	—	—	(600)	$ 1.55	—	—
Forfeited	(403,024)	$ 5.23	—	—				
Outstanding as of September 30, 2023	6,913,348	$ 8.86	7.5	$ 79				
Exercisable as of September 30, 2023	3,720,545	$ 12.43	6.3	$ 79				
Forfeitures					(445,998)	$ 2.27	—	—
Outstanding as of March 31, 2024					9,206,104	$ 6.94	7.7	3,032
Exercisable as of March 31, 2024					4,461,149	$ 11.43	6.1	$ 763

(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at September 30, 2023 December 31, 2023 and December 31, 2022 March 31, 2024.

The weighted average grant date fair value of stock options granted to employees for the nine three months ended September 30, 2023 March 31, 2024 was $1.12 $1.22 using the Black-Scholes option pricing model. There were 5,057 600 stock options exercised during the nine three months ended September 30, 2023 March 31, 2024. As of September 30, 2023 March 31, 2024, there was $9.7 million $8.8 million of total unrecognized compensation expense related to unvested options under the Plans that will be recognized over a weighted-average period of approximately 1.8 years.

The aggregate grant date fair value of stock options vested during the three months ended March 31, 2024 and 2023 was approximately $2.0 million and $2.9 million, respectively.

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited) (*unaudited*)

compensation expense related to unvested options under the Plans that will be recognized over a weighted-average period of approximately 1.9 years.

The aggregate grant date fair value of stock options vested during the nine months ended September 30, 2023 and 2022 was approximately $7.2 million and $9.0 million, respectively.

Stock-based compensation expense was classified on the statements of operations as follows for the three and nine months ended September 30, 2023 March 31, 2024 and 2022: 2023:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,		Three Months Ended	
	2023	2022	2023	2022	2024	2023
Research and development	$ 721	$ 779	$ 2,184	$ 2,274	$ 669	$ 722
General and administrative	1,280	1,533	4,020	4,908	1,024	1,356
Total stock-based compensation expense	$ 2,001	$ 2,312	$ 6,204	$ 7,182	$ 1,693	$ 2,078

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:

	Nine Months Ended September 30,		Three Months Ended March 31,	
	2023	2022	2024	2023
Expected term	6.1 years	5.5 - 6.1 years	6.1 years	6.1 years
Expected volatility	81.4 %	79.7 %	83.3 %	81.4 %
Risk free interest rate	3.5 - 4.1 %	1.8 - 3.1 %	3.9-4.2 %	3.6 - 4.1 %
Expected dividend yield	— %	— %	— %	— %

Employee Stock Purchase Plan

The NextCure, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") was approved in May 2019 and provides for eligible employees of the Company to purchase shares of Company stock at a discounted price. As of September 30, 2023 March 31, 2024, 109,958 173,017 shares of common stock had been issued pursuant to the ESPP and 680,722 896,693 shares were reserved for future issuance thereunder.

7. Collaboration Agreements

Collaboration Agreement with LegoChem LigaChem Biosciences, Inc. ("LegoChem" LigaChem"), formerly known as LegoChem Biosciences

In November 2022, the Company entered into a Research Collaboration and Co-Development Agreement ("Agreement") with LegoChem LigaChem to develop up to three antibody drug conjugates. Under the terms of the Agreement, both parties equally share the costs of developing the molecules and profits on commercialized products. The collaboration consists of up to three research programs for which a research plan will be developed. With respect to a research plan, each party shall use reasonable efforts to execute and perform the activities assigned to it. Each party shall be solely responsible for costs associated with its assigned activities as outlined in the research plan. Upon successful completion of a research plan, or as otherwise agreed, the parties may designate a research product as a co-development product. Upon designation of a co-development product, cost sharing on a 50-50 basis between the Company and LegoChem LigaChem would begin. The activities associated with the research plan and co-development products will be coordinated by a joint steering committee, which is comprised of an equal number of representatives from the Company and LegoChem. LigaChem. If and when a co-development product becomes commercialized, the Company and LegoChem LigaChem would equally share in the profits. There are no implied licenses or other rights created under this Agreement after designation of a co-development product.

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)

Effective April 1, 2023, the parties designated the initial co-development product under the Agreement. As such, cost sharing on a 50-50 basis commenced for the first co-development product under the Agreement.

Given the involvement by both parties under this Agreement, management assessed the criteria under ASC 808 to determine if such agreement is within the scope of ASC 808. Based on the terms of the Agreement, the Company concluded that the Agreement meets the requirements of a collaboration within the guidance of ASC 808. The Company

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(*unaudited*)

and LegoChem LigaChem are active participants in the activities associated with the Agreement and are exposed to significant risks and rewards dependent on the commercial success of the activity. The Agreement is not reflective of a vendor-customer relationship and therefore not within the scope of ASC 606. Accordingly, the net costs associated with the co-development pursuant to the Agreement are expensed as incurred and recognized within research and development expenses on the statement of operations.

As of September 30, 2023 March 31, 2024, there is only one LNCB74 was the lone co-development product that is and was in the early stages of development development. During the three months ended March 31, 2024, the Company incurred more costs than LigaChem under the Agreement, and recorded a receivable from LigaChem and a corresponding reduction of $0.8 million in costs, incurred have not reflecting the 50-50 cost sharing terms under the Agreement.Further, the Company and LigaChem finalized the cost sharing adjustments from the fourth quarter of 2023, resulting in an additional $1.6 million receivable and a corresponding reduction in costs that was recorded in the first quarter of 2024.

8. Restructuring and Asset Impairment

On March 19, 2024, the Board approved a restructuring plan and prioritization (the “2024 Restructuring”) of its clinical portfolio to focus on what the Company believes to be its highest-value opportunities in NC410 (ovarian and colorectal cancer) and LNCB74 (B7-H4 ADC). In addition to prioritizing these programs, the Company paused its internal manufacturing operations and reduced its workforce by approximately 37%.

Employees affected by the reduction in force under the 2024 Restructuring are entitled to receive severance payments and Company-funded medical insurance for a specified time. During the three months ended March 31, 2024, the Company recognized $0.8 million for employees who had no requirements for future service upon approval of the 2024 Restructuring.

The following table summarizes the activity for accrued severance costs for the three months ended March 31, 2024 (in thousands):

	2024
Severance accrual, January 1	$ -
Charges	755
Cash payments	(120)
Severance accrual, March 31	$ 635

The accrued severance liability of $0.6 million is payable within the next three months and has been material. included as accrued severance costs in accrued liabilities and other liabilities on the condensed balance sheet.

The Company also completed an evaluation of the impact of the 2024 Restructuring on the carrying value of its long-lived assets. Our evaluation determined that indicators of impairment were present within right of use assets and property and equipment. Where impairment indicators existed, the Company evaluated the identified asset group and separately compared the estimated undiscounted cash flow for each asset group to the net book value of the related long-term asset. Based on this evaluation, the Company determined an impairment was present and then calculated the amount of the impairment by developing a fair value estimate of the asset group that was compared to the carrying value.

The Company recorded $1.8 million of impairment charges related to a facility operating lease asset and accelerated depreciation on manufacturing equipment as of and for the three-months ended March 31, 2024.

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(*unaudited*)

Assumptions used in this analysis included current real estate trends, length of time to enter into a sublease and the discount rate used to develop the present value estimate. Other assumptions included an estimate of the salvage value for manufacturing equipment that is no longer in use. These assumptions are considered nonrecurring Level 3 estimates.

8. 9. Net Loss Per Share Attributable to Common Stockholders

The computation of basic loss per share is based on the weighted-average number of common shares outstanding, without consideration for dilutive common stock equivalents. The computation of diluted loss per share is based on the weighted-average number of common shares outstanding and dilutive potential common shares, which include shares that may be issued under the 2015 Plan and 2019 Plan, as determined using the treasury stock method.

The computation for basic and diluted loss per share were as follows (in thousands, except share and per share data):

	Three Months Ended September 30,		Nine Months Ended September 30,		Three Months Ended March 31,	
	2023	2022	2023	2022	2024	2023
Net loss (Numerator):						

Net loss - basic and diluted	$ (14,301)	$ (18,911)	$ (48,256)	$ (57,433)	$ (17,107)	$ (16,096)
Shares (Denominator):						
Weighted-average shares outstanding - basic and diluted	27,839,968	27,748,844	27,814,655	27,734,271	27,903,040	27,774,536
Loss per share - basic and diluted	$ (0.51)	$ (0.68)	$ (1.73)	$ (2.07)	$ (0.61)	$ (0.58)

For the three and nine months ended September 30, 2023 March 31, 2024 and 2022, 2023, all options to purchase shares of the Company's common stock were excluded from the computation of diluted net loss per share as the effect would have been anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.

The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:

	September 30,		March 31,	
	2023	2022	2024	2023
Outstanding options to purchase common stock	6,913,348	5,276,833	9,206,104	7,030,160
Total			9,206,104	7,030,160

Table of Contents

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(unaudited)

9. 10. Income Taxes

The Company did not record a provision or benefit for income taxes during the three and nine month periods ended September 30, 2023 March 31, 2024 and 2022. 2023. The Company continues to maintain a full valuation allowance against its deferred tax assets.

The Company has evaluated the positive and negative evidence involving its ability to realize its deferred tax assets. Management has considered the Company's history of cumulative net losses incurred since inception and its lack of any commercially ready products. It has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Management reevaluates the positive and negative evidence at each reporting period.

Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the "IRC"), certain substantial changes in the Company's ownership may have limited, or may limit in the future, the amount of net operating loss and research and development credit carryforwards that can be used to reduce future income taxes. We have

NEXTCURE, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(*unaudited*)

not performed a detailed analysis to determine whether an ownership change under Section 382 of the IRC occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of losses and credits attributable to periods before the change and could result in a reduction in the total losses and credits available.

10. 11. Commitments and Contingencies

Legal Proceedings

On September 21, 2020, From time to time, the Company is a putative stockholder class action was filed party to litigation or legal proceedings arising in the U.S. District Court for ordinary course of business. The Company is not currently a party to any litigation or legal proceeding, nor is management aware of any pending or threatened litigation that, in the Southern District opinion of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.) (the "Ye Zhou Action"). On February 26, 2021, the Lead Plaintiff filed Company's management, is likely to materially affect the Company's business or financial results. At each reporting date, the Company evaluates whether a consolidated amended complaint that asserts claims against us, certain potential loss amount or a potential range of our officers loss is probable and members of our board of directors, and reasonably estimable under the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as amended (the "Exchange Act"), and the Securities Act of 1933, as amended (the "Securities Act"), with respect to statements made regarding the Company's NC318 product candidate and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021, and on July 12, 2023 the court issued a memorandum opinion and order granting defendants' motion to dismiss against all counts of the consolidated amended complaint. On July 13, 2023, judgement on behalf of Company and the other named defendants was entered and the case for the Ye Zhou Action was closed by the court. No appeals were filed by plaintiffs in the Ye Zhou to contest the district court's order dismissing all claims in favor of Company.

On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754 (the "Liu Action"), alleging breaches of fiduciary duty by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act. The complaint seeks unspecified damages, attorneys' fees and costs, declaratory relief, corporate governance changes, and restitution. On May 17, 2021, the Court granted the parties' joint motion to stay the Liu Action pending resolution of the defendants' motion to dismiss filed in respect of the Ye Zhou Action. On August 1, 2023, Company filed a notice with the court in the Liu Action advising of the result of the motion to dismiss an entry of judgement in the Ye Zhou Action. On August 22, 2023, the Liu Action plaintiff filed a stipulation with the court to dismiss voluntarily all claims against Company, and the court in response closed the case for the Liu Action. incurred.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto included in this Quarterly Report and the audited financial information and related notes, as well as Management's Discussion and Analysis of Financial Condition and Results of Operations and other disclosures, included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 December 31, 2023, or our "2022 "2023 Annual Report." Some of the statements contained in this discussion and analysis or set forth elsewhere in this Quarterly Report are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "continue," "could," "should," "due," "estimate," "expect," "intend," "hope," "may," "objective," "plan," "predict," "project," "potential," "positioned," "seek," "target, "should," "towards," "forward," "later, "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language. Forward-looking statements include, but are not limited to, statements about:

- our expectations regarding the timing, progress and results of preclinical studies and clinical trials for NC410, NC525, NC762 LNCB74 and any other product candidates we develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;
- the timing or likelihood of regulatory filings for NC410, NC525, NC762 LCNB74 and any other product candidates we develop and our ability to obtain and maintain regulatory approvals for such product candidates for any indication;
- *the*the identification, analysis and use of biomarkers and biomarker data;
- *development of patient selection assays and companion or complementary diagnostics for NC410, NC525, NC762 and any other product candidates we develop;*
- the anticipated benefits of our recently announced prioritization and restructuring plan;
- our drug product sourcing and manufacturing capabilities and strategy, including the scalability of our manufacturing methods and processes;
- our expectations regarding the potential benefits, activity, effectiveness and safety of NC410, NC525, NC762 LNCB74 and any other product candidates we develop;
- our intentions and ability to successfully commercialize, including through partnering, our product candidates;
- our expectations regarding the nature of the biological pathways we are targeting;
- our expectations for our Functional, Integrated, NextCure Discovery in Immuno-Oncology ("FIND-IO") platform, including regarding our ability to discover and advance product candidates using our FIND-IO platform;technologies;
- the potential benefits of and our ability to maintain our relationship and collaboration with Yale University;University, LigaChem Biosciences, Inc. and other third parties;
- our ability to retain key personnel;
- our estimates regarding our expenses, future revenues, capital requirements, our needs for or ability to obtain additional financing and the period over which we expect our current cash, cash equivalents and marketable securities to be sufficient to fund our operations;
- our intended reliance on and the performance of third parties, including collaborators, contract research organizations and third-party manufacturers;

Table of Contents

- our ability to protect and enforce our intellectual property protection and the scope and duration of such protection;

- *any failure of our information technology systems such as security breaches, loss of data and other disruptions;*
- developments and projections relating to our competitors and our industry, including competing therapies; and
- the impact of current and future laws and regulations.

Table of Contents

Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; our limited operating history and not having any products approved for commercial sale; our history of significant losses; our need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on our FIND-IO platform; technologies; risks related to our restructuring and reduction in force; and our dependence on key personnel. *More detailed information on these and additional factors that could affect our actual results are described under the heading "Risk Factors" in our 2022 2023 Annual Report and in our other filings with the Securities and Exchange Commission ("SEC" (the "SEC"). You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this report, and we assume no obligation to update any forward-looking statements, even if expectations change.*change.

Overview

We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates ("ADCs"), antibodies and other immune-related diseases by restoring normal immune function. proteins. We view the immune system holistically and, rather than target one specific immune cell type, we focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in an immune a biologic response. Through our proprietary FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition.

Our product candidate NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 and that is designed to block immune suppression mediated by LAIR-1. In June 2020, we initiated Early preclinical correlative biomarker work suggests that NC410 has the potential to overcome tumor resistance by remodeling the tumor's extracellular matrix to remove a Phase 1/2 clinical trial of NC410 in patients with advanced or metastatic solid tumors. The Phase 1 dose-escalation portion of this open-label trial was designed physical barrier surrounding the tumor to evaluate the safety and tolerability of NC410 and determine its pharmacologically active and/or maximum tolerated dose. In October 2022, we announced the initiation of enhance T cell tumor killing. We have exclusive worldwide rights to NC410. We are currently conducting a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA® (pembrolizumab), Merck's Merck & Co., Inc.'s (Merck) anti-PD-1 therapy, in therapeutic. Based on clinical responses and biomarker observations, we are focused on ovarian cancer and colorectal cancer (CRC) patients who are immune checkpoint refractory inhibitor (ICI) naïve. In January 2024, we completed enrollment of an additional 20 CRC patients (colorectal, esophageal, endometrial in the 100 mg cohort and head in March 2024 we commenced enrolling an additional 18 ovarian patients among the 100 mg and neck cancers) or immune checkpoint naïve solid

tumor patients (colorectal 200 mg cohorts. We expect to present CRC data at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024 and ovarian cancers). We plan to provide an update on cancer data in the Phase 1b portion second half of the trial by year end. this year.

Our product candidate NC762 LNCB74 is designed as a state-of-the-art B7-H4 targeted ADC to kill tumors. An ADC consists of a monoclonal antibody that binds specifically conjugated to human B7 homolog 4 protein, or "B7-H4", a cytotoxic drug via a chemical linker. B7-H4, a clinically validated target, is a cell surface protein expressed on multiple tumor types. In July 2021, types including breast, ovarian, and endometrial cancers, that we initiated believe represents a Phase 1/2 clinical trial of NC762 in patients large market opportunity. LNCB74 will be positioned as a promising B7-H4 ADC with lung cancer, breast cancer, ovarian cancer or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial was designed to evaluate the both improved safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. In efficacy. LNCB74 is being advanced under a November 2022 we announced initial data from the Phase 1 portion of this trial which indicate that NC762 appears to be well tolerated. Safety expansion studies are ongoing with the intent of selecting a recommended Phase 2 dose. We plan to provide an update on the Phase 1b portion of the trial by year end.

Our product candidate NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or "AML", blast cells and leukemic stem cells, or "LSCs". Preclinical data show that NC525 kills AML blast cells and LSCs

---

Table of Contents

while sparing hematopoietic stem and progenitor cells, or "HSPCs". In February 2023 we initiated a Phase 1 trial for NC525 to evaluate the safety and preliminary efficacy of NC525 in AML, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia (CMML). We plan to provide an operational update on the Phase 1a portion of the trial by year end.

In November 2022, the Company entered into a Research Collaboration and Co-Development Agreement ("LigaChem Agreement") with LegoChem LigaChem Biosciences, Inc's "(LigaChem"). To date, we have completed i) pre-clinical experiments *in vitro* and *in vivo* demonstrating potent tumor killing, ii) pilot toxicology studies, iii) received pre-IND feedback from the FDA, and iv) we are conducting ongoing activities associated with GLP toxicology studies, GMP manufacturing, and clinical development planning. We plan to develop up file an Investigational New Drug application (IND) in the fourth quarter of 2024.

In March 2024, we announced a prioritization and restructuring of our operations to three antibody drug conjugates. Under align with our focused pipeline. We paused our internal manufacturing operations and reduced our workforce. We expect these actions to extend our cash runway into the terms second half of the Agreement, both parties equally share the costs of developing the molecules 2026. In addition, we are seeking to partner our clinical programs NC525 and profits on commercialized products. In April 2023, the parties designated the initial co-development candidate under the Agreement will target B7-H4. LNCB74, NC318 and our first candidate, will utilize a NextCure B7-H4 antibody and LegoChem's ConjuAll ™ ADC technology. Early Phase 1 data presented in October 2023 by other companies at the European Society for Medical Oncology (ESMO) 2023 Congress demonstrated the efficacy of attacking this target in selected tumor types.

We recently announced two novel preclinical non-oncology programs NC605 for chronic bone diseases, and NC181. NC605, an anti-Siglec-15 antibody, preclinical data reported reduced bone loss and enhanced bone quality in mice with osteogenesis imperfecta (OI). OI is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility and recurrent fractures. We are evaluating the future development path NC181 for this candidate which may include seeking a partner for further development. The second preclinical program, NC181, is a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease (AD). In preclinical AD animal models, NC181 has demonstrated amyloid clearance, prevention of amyloid

deposition, plaque clearance and other important findings. We are seeking a partner for further development of this candidate. disease.

Financial Overview

Since commencing operations in 2015, we have devoted substantially all our efforts and financial resources to organizing discovery, research and staffing our company, development activities for the Company's product candidates, identifying business development opportunities, raising capital, securing intellectual property rights related to our the Company's product candidates building and optimizing our manufacturing capabilities, organizing and conducting discovery, research and development activities for our product candidates, discovery programs and FIND-IO platform. staffing the Company.

Table of Contents

To date, we have not generated any revenue from product sales and have financed our operations primarily through proceeds from public offerings of our common stock, with private placements of our preferred stock and with upfront fees received under our former research and development collaboration agreement. Since inception through September 30, 2023 March 31, 2024, we raised approximately $423 million in gross proceeds from the sale of equity instruments and had previously received a $25 million upfront payment from our former collaboration partner. Our net loss for the three months ended September 30, 2023 March 31, 2024 and 2022, 2023, was $14.3 million $17.1 million and $18.9 million, respectively. Our net loss for the nine months ended September 30, 2023 and 2022, was $48.3 million and $57.4 million $16.1 million, respectively. As of September 30, 2023 March 31, 2024, we had an accumulated deficit of $310.0 million $341.6 million, primarily as a result of research and development and general and administrative expenses. We do not expect to generate product revenue unless and until we obtain marketing approval and commercialize a product candidate, and we cannot assure you that we will ever generate significant revenue or profits.

As of September 30, 2023 March 31, 2024, we had cash, cash equivalents and marketable securities of $118.2 million $96.0 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into mid-2025. the second half of 2026. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect.

We expect to incur substantial expenditures in the foreseeable future as we advance our product candidates through clinical development, the regulatory approval process and, if approved, commercialization. Specifically, in the near term, we expect to incur substantial expenses relating to our Phase 1b/2 clinical trial of NC410 in combination with pembrolizumab, our ongoing Phase 1/2 clinical trial for NC762, our Phase 1 clinical trial for NC525, pre-clinical development activities with respect to LNCB74 and other research and development activities. We expect to continue to incur significantly increased costs as a result of operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company.

Table of Contents

We will need substantial additional funding to support our continuing operations and to pursue our development strategy. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through a combination of public and private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.

Components of Our Results of Operations

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our clinical trials, discovery efforts, research activities, and development and testing of our product candidates:

- expenses incurred under agreements with third parties, including agreements with third parties that conduct research, preclinical activities or clinical trials on our behalf;
- costs of outside consultants, including their fees, stock-based compensation and related travel expenses;
- the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;
- salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; and
- facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

We expense research and development costs as incurred. Our expenses related to clinical trials are based on actual costs incurred and estimates of other incurred costs. These estimated costs are based on several factors, including patient

---

Table of Contents

enrollment and related expenses at clinical investigator sites, contract services received, consulting agreement costs and efforts expended under contracts with research institutions and third-party contract research organizations that conduct and manage clinical trials on our behalf. We generally accrue estimated costs related to clinical trials based on contracted amounts applied to the level of patient enrollment and other activity according to the protocol. If future timelines or contracts are modified based on changes in the clinical trial protocol or scope of work to be performed, we would modify our estimates of accrued expenses accordingly on a prospective basis. Historically, any such modifications have not been material.

Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for in the foreseeable future as we advance our product candidates through development and expand the number of trials we are conducting and the patients enrolled in those trials, as we utilize our current good manufacturing practice, or “cGMP”, manufacturing capacity, including to provide drug supply of NC410, NC762 and NC525 for future clinical trials. development.

Table of Contents

We cannot determine with certainty the duration and costs of future clinical trials of NC410, NC762, NC525 LNCB74 or any other product candidate we may develop or if, when or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we may obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of NC410, NC762, NC525 LNCB74 and any other product candidate we may develop will depend on a variety of factors, including:

- the scope, progress, results and costs of clinical trials of NC410 NC762 and NC525, LNCB74, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct;
- uncertainties in selection of indications, clinical trial design and patient enrollment rates;
- the probability of success for our product candidates, including safety and efficacy, early clinical data, competition, ease and ability of manufacturing and commercial viability;
- significant and changing government regulation and regulatory guidance;
- the timing and receipt of any development or marketing approvals; and
- the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

A change in the outcome of any of these variables with respect to the development of a product candidate could lead to a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time to complete clinical development for any such product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel related costs, including payroll and stock- based compensation, for personnel in executive, finance, human resources, business and corporate development and other administrative functions, professional fees for legal, intellectual property, consulting and accounting services, rent and other facility-related costs, depreciation and other general operating expenses not otherwise classified as research and development expenses. General and administrative expenses also include all patent-related costs incurred in connection with filing and prosecuting patent applications, which are expensed as incurred.

We anticipate*Restructuring and Asset Impairment Charges*

Restructuring and asset impairment charges consist of severance charges associated with a reduction in force, and include salary continuation, payroll taxes and company funded benefits. Asset impairment charges reflect the write-down of long-lived assets that our general and administrative expenses will increase during the next few years as a result are considered impaired under ASC 360.

Table of staff costs, additional occupancy costs, higher legal and accounting fees, investor relations costs, higher insurance premiums and other compliance costs. Contents

Other Income, Net

Other income, net consists primarily of interest income earned on marketable securities.

Table of Contents

Results of Operations

Comparison of the Three and Nine Months Ended September 30, 2023 March 31, 2024 and 2022 2023

The following table summarizes our results of operations for the periods indicated (in thousands):

	Three Months Ended September 30,			Nine Months Ended September 30,			Three Months Ended March 31,		
	2023	2022	Change	2023	2022	Change	2024	2023	Change
Operating expenses:									
Research and development	$ 11,010	$ 13,528	$ (2,518)	$ 36,104	$ 41,377	$ (5,273)	$ 11,398	$ 11,647	$ (249)
General and administrative	4,608	5,711	(1,103)	15,743	16,761	(1,018)	4,364	5,424	(1,060)
Restructuring and asset impairment charges							2,542	—	2,542
Loss from operations	(15,618)	(19,239)	3,621	(51,847)	(58,138)	6,291	(18,304)	(17,071)	(1,233)
Other income, net	1,317	328	989	3,591	705	2,886	1,197	975	222
Net loss	$ (14,301)	$ (18,911)	$ 4,610	$ (48,256)	$ (57,433)	$ 9,177	$ (17,107)	$ (16,096)	$ (1,011)

Research and Development Expenses

The following table summarizes our research and development expenses by product candidate for the periods indicated (in thousands):

(in thousands)	Three Months Ended September 30,			Nine Months Ended September 30,			Three Months Ended March 31,		
	2023	2022	Change	2023	2022	Change	2024	2023	Change
External research and development expenses:									
NC410	$ 1,526	$ 1,465	$ 61	$ 5,336	$ 4,785	$ 551	$ 2,937	$ 1,300	$ 1,637
NC762	740	1,448	(708)	2,834	3,593	(759)			
NC525	1,085	1,124	(39)	2,429	3,475	(1,046)			
LNCB74, net of cost sharing							889	—	889
Other programs and preclinical development	2,035	3,373	(1,338)	7,612	11,944	(4,332)	4,013	4,206	(193)
Total external research and development expenses	5,386	7,410	(2,024)	18,211	23,797	(5,586)	7,839	5,506	2,333
Total internal research and development expenses	5,624	6,118	(494)	17,893	17,580	313	3,559	6,141	(2,582)

Total research and development expenses	$11,010	$13,528	$(2,518)	$36,104	$41,377	$(5,273)	$11,398	$11,647	$ (249)

We do not allocate personnel-related costs, including stock-based compensation costs, or other indirect costs to specific programs, as they are deployed across multiple projects under development and discovery and, as such, are separately classified as internal research and development expenses in the table above.

Research and development expenses for the three months ended September 30, 2023 March 31, 2024 decreased $2.5 million, or 19% by $0.2 million compared to the three months ended September 30, 2022 March 31, 2023, as higher costs associated with adding patients in our Phase 1b clinical trial of NC410 in patients with ovarian cancer and colorectal cancer and net costs for the LNCB74 program were offset by lower internal costs, primarily due to lower reimbursement of costs associated subject to cost sharing under our collaboration with our Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types, as well as lower costs on other programs and preclinical development.

Research and development expenses for the nine months ended September 30, 2023 decreased $5.3 million, or 13% compared to the nine months ended September 30, 2022, primarily due to the decision to discontinue clinical development of NC318 announced in the fourth quarter of 2022 LigaChem and lower costs associated with NC525, as this program initiated a phase 1 trial in February 2023, and lower costs on other programs and preclinical development.personnel-related costs.

General and Administrative Expenses

General and administrative expenses for the three months ended March 31, 2024 decreased by $1.1 million compared to the three months ended March 31, 2023. The decrease was primarily due to lower payroll, lower stock compensation expense and lower insurance costs.

Table of Contents

General*Restructuring and administrative expenses Asset Impairment Charges*

Restructuring and asset impairment charges were $2.5 million for the three months ended September 30, 2023 decreased by $1.1 million compared to March 31, 2024, consisting of $0.7 million of severance charges as a result of a reduction in force announced on March 21, 2024, and $1.8 million of asset impairment charges associated with the write-down of certain manufacturing equipment, right of use assets and related improvements as a result of the pause in manufacturing that we announced on March 21, 2024. There were no restructuring and asset impairment charges in the three months ended September 30, 2022 March 31, 2023. The increase was primarily due to lower payroll, lower stock compensation expense, lower insurance costs and lower legal costs.

General and administrative expenses for the nine months ended September 30, 2023 decreased by $1.0 million compared to the nine months ended September 30, 2022. The decrease was primarily due to lower stock compensation costs, lower insurance costs and lower professional fees partially offset by higher legal costs.

Other Income, Net

Other income, net for the three months ended September 30, 2023 March 31, 2024 increased by $1.0 million $0.2 million compared to the three months ended September 30, 2022 March 31, 2023, due to higher interest income as a result of higher interest rates and lower amortization on our investments.

Other income, net for the nine months ended September 30, 2023 increased by $2.9 million compared to the nine months ended September 30, 2022, due to higher interest income as a result of higher interest rates and lower amortization on our investments.

Liquidity and Capital Resources

We have financed our operations primarily with proceeds from public offerings of our common stock, private placements of our preferred stock and upfront fees received under the Company's former agreement with Eli Lilly and Company, which was terminated in March 2020 (the "Lilly Agreement"). On May 13, 2019, we closed our IPO, in which we sold 5,750,000 shares of common stock at a public offering price of $15.00 per share, for net offering proceeds to us of approximately $77.0 million after deducting underwriting discounts and commissions and offering expenses. On November 19, 2019, we completed an underwritten public offering in which we sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at a public offering price of $36.75. Net offering proceeds to us were approximately $160.9 million after deducting underwriting discounts and commissions and offering expenses. Since inception, we have received aggregate gross proceeds of $164.4 million from the sale and issuance of shares of our preferred stock. In addition, in November 2018, we received an upfront payment of $25.0 million in cash from Lilly pursuant to the Lilly Agreement. Our cash and cash equivalents are held in money market funds.

On August 4, 2023, the Company entered into a sales agreement (the "Sales Agreement") with Leerink Partners LLC (the "Agent"), pursuant to which the Company may sell, from time to time, up to an aggregate sales price of $75 million of its common stock through the Agent in negotiated transactions that are deemed to be an "at the market offering." The Agent will be entitled to compensation equal to 3.0% of the gross proceeds from the sale of all shares of common stock sold through it as Agent under the Sales Agreement. Actual sales will depend on a variety of factors to be determined by the Company from time to time, including, among other things, market conditions, the trading price of the common stock, capital needs and determinations by the Company of the appropriate sources of funding for the Company. We have not yet sold any As of March 31, 2024, no shares of our common stock had been sold pursuant to the Sales Agreement.

As of September 30, 2023 March 31, 2024, we had cash, cash equivalents and marketable securities of $118.2 million $96.0 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into mid-2025. the second half of 2026.

We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through sale of equity, debt financings, strategic alliances and licensing arrangements. Adequate additional funding may not be available to us on acceptable terms or at all. If we fail to raise capital or enter into such arrangements as and when needed, we may have to significantly delay, scale back or discontinue the development of our product candidates or delay our efforts to expand our pipeline of product candidates.

Table of Contents

Cash Flows

The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):

	Nine Months Ended September 30,	Three Months Ended March 31,

	2023	2022	2024	2023
Net cash (used in) provided by:				
Operating activities	$ (42,304)	$ (44,937)	$(12,606)	$(14,779)
Investing activities	35,110	63,511	17,881	18,122
Financing activities	83	139	1	—
Net increase (decrease) in cash and cash equivalents	$ (7,111)	$ 18,713		
Net increase in cash and cash equivalents			$ 5,276	$ 3,343

Net Cash Used in Operating Activities

Net cash used in operating activities was $42.3 million $12.6 million for the nine three months ended September 30, 2023 March 31, 2024, which was primarily the result of our net loss of $48.3 million $17.1 million, partially offset by non-cash charges for depreciation of $0.8 million, stock-based compensation of $1.7 million and impairment charges of $1.8 million, and $0.4 million provided by net changes in operating assets and liabilities. Net cash used in operating activities was $14.8 million for the three months ended March 31, 2023, which was primarily the result of our net loss of $16.1 million and a $3.1 million $2.0 million net use of operating assets and liabilities, partially offset by non-cash charges for depreciation and amortization of $2.9 million $1.0 million and stock-based compensation of $6.2 million. Net cash used in operating activities was $44.9 million for the nine months ended September 30, 2022, which was primarily due to our net loss of $57.4 million, partially offset by non-cash charges for depreciation and amortization of $3.1 million, amortization of premiums and discounts on marketable securities of $2.6 million, and stock-based compensation of $7.2 million $2.1 million.

Net Cash Provided by Investing Activities

Net cash provided by investing activities for the nine three months ended September 30, 2023 March 31, 2024 was $35.1 million $17.9 million, which was primarily due to net proceeds from sales and maturities of marketable securities of $35.9 million $17.9 million. Net cash provided by investing activities for the three months ended March 31, 2023 was $18.1 million, which was primarily due to net proceeds from maturities of marketable securities of $18.4 million, partially offset by purchases of property and equipment of $0.8 million. Net cash provided by investing activities for the nine months ended September 30, 2022 was $63.5 million, which was primarily due to net proceeds from marketable securities of $64.8 million, partially offset by purchases of property and equipment of $1.3 million $0.2 million.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was $0.1 million $1,000 for the nine three months ended September 30, 2023 March 31, 2024 representing sales of our stock under the Employee Stock Purchase Plan (ESPP) and the exercise of stock options. Net cash provided by financing activities was $0.1 million $0 for the nine three months ended September 30, 2022, representing sales of our stock under the Employee Stock Purchase Plan (ESPP) and the exercise of stock options. March 31, 2023.

Contractual Obligations and Commitments

There have been no material changes to our contractual obligations during the nine three months ended September 30, 2023 March 31, 2024, as compared to those disclosed in our 2022 2023 Annual Report.

Critical Accounting Policies, Significant Judgments and Use of Estimates

Our condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or “GAAP”. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. The most significant assumptions used in the financial statements are the underlying assumptions used in revenue recognition and valuing share-based compensation, including the fair value of our common stock in periods before our IPO. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent

Table of Contents

from other sources. We evaluate our estimates and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions.

Table of Contents

During the nine three months ended September 30, 2023 March 31, 2024, there were no material changes to our critical accounting policies reported in our 2022 2023 Annual Report.

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Recent Accounting Pronouncements

See Note 2 to our unaudited condensed financial statements included elsewhere in this Quarterly Report for a discussion of recent accounting pronouncements that may impact our financial position and results of operations.

Emerging Growth Company Status

As an emerging growth company, or "EGC", under the Jumpstart Our Business Startups Act of 2012, or the "JOBS Act", we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. We have elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies until such time as those standards apply to private companies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a "smaller reporting company" as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the (the "Exchange Act"), we are not required to provide the information requested by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of

September 30, 2023 March 31, 2024. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2023 March 31, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that occurred during the quarter ended September 30, 2023 March 31, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

The information set forth under the heading “Legal Proceedings” in Note 9, 10, Commitments and Contingencies, in Notes to Condensed Financial Statements in Item 1 of Part I of this Quarterly Report, is incorporated herein by reference. In addition, from time to time, we are involved in litigation or other legal proceedings as part of our ordinary course of business. In the opinion of our management, the ultimate disposition of these legal proceedings in the ordinary course of business is not likely to have a material adverse effect on our business.

Item 1A. Risk Factors.

There have been no material updates to the risk factors set forth in our 2022 2023 Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

During the fiscal quarter ended September 30, 2023 March 31, 2024, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was

intended to satisfy the affirmative defense conditions of Rule 10b5-1 or any non-Rule 10b5-1 trading arrangement.

Table of Contents

Item 6. Exhibits.

The exhibits filed or furnished as part of this Quarterly Report are set forth on the Exhibit Index, below.

Exhibit No.	Exhibit Description
31.1	Certification of Michael Richman pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Steven P. Cobourn pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Michael Richman and Steven P. Cobourn pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
EX-101.INS	Inline XBRL Instance Document
EX-101.SCH	Inline XBRL Taxonomy Extension Schema Document
EX-101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
EX-101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
EX-101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
EX-101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Coverage Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NEXTCURE, INC.

Date: November 2, 2023 May 2, 2024

By: /s/ Michael Richman
Name: Michael Richman
President and Chief Executive Officer

Date: November 2, 2023 May 2, 2024

By: /s/ Steven P. Cobourn
Name: Steven P. Cobourn
Chief Financial Officer

EXHIBIT 31.1

Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Michael Richman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of NextCure, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

   (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2023 May 2, 2024

/s/ Michael Richman

Name: Michael Richman

Title: President and Chief Executive Officer

EXHIBIT 31.2

Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Steven P. Cobourn, certify that:

1. I have reviewed this quarterly report on Form 10-Q of NextCure, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2023 May 2, 2024

/s/ Steven P. Cobourn

Name: Steven P. Cobourn
Title: Chief Financial Officer

/div>

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of NextCure, Inc. (the "Company") for the quarter ended September 30, 2023 March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned each hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge, on the date hereof:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 2, 2023 May 2, 2024

/s/ Michael Richman

Name: Michael Richman

Title: President and Chief Executive Officer

Dated: November 2, 2023 May 2, 2024

/s/ Steven P. Cobourn

Name: Steven P. Cobourn

Title: Chief Financial Officer

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

REFINITIV